Andrea Mahr,Toni Weinschenk,Oliver Schoor,Jens Fritsche,Harpreet Singh,Phillip Mueller,Julia Leibold,Valentina Goldfinger
申请号：
US15637906
公开号：
US09993539B2
申请日:
2017.06.29
申请国别(地区):
US
年份:
2018
代理人:
摘要：
A method of treating a patient who has liver cancer (HCC), breast cancer (BRCA), melanoma, and/or uterine cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has HCC, BRCA, melanoma, and/or uterine cancer.
